SimBioSys Wins FDA Clearance for Breast Cancer Recurrence AI Tool

SimBioSys announced on October 15, 2026 that the U.S. Food and Drug Administration has granted 510(k) clearance to TumorSight Risk, an artificial intelligence software device that analyzes breast MRI scans alongside pathology and clinical data to estimate a patient’s risk of breast cancer recurrence at five and ten years. In its announcement, the Chicago-based company…

Read More

Customs Compliance Is Becoming an AI Problem

The Importer of Record Is Becoming a Data Problem Customs compliance has traditionally been treated as a transaction-level exercise. Classify the product, calculate the duty, file the entry, and retain the records. That model is becoming harder to sustain as customs authorities demand more visibility into the companies, products, and supply chains behind each import….

Read More

Bloomberg’s ASKB Conversational AI Reaches General Availability

Bloomberg announced on October 15, 2026 that ASKB, the Bloomberg Terminal’s conversational AI interface, is now generally available to financial professionals, with expanded capabilities that let clients bring their own Instant Bloomberg chats, Worksheets, and files into its AI conversations. Wayne Barlow, Global Head of Core Terminal Products at Bloomberg, said that until now some…

Read More

Why Better Data Alone Isn’t Enough for AI Agents

For years, one of the most common pieces of advice for enterprise AI has been to get the data right first. The logic is straightforward: if a system is going to make useful decisions, it needs accurate, accessible information to work with. That statement remains true today, but it is becoming incomplete as AI agents…

Read More
Back To Top